LONDON (Alliance News) - Drugmaker AstraZeneca PLC on Friday said the US Food & Drug Administration has issued a complete response letter on the new drug application made for sodium zirconium cyclosilicate, while also saying it secured good results from its Faslodex trials.
AstraZeneca said its faslodex drug met its primary endpoint for treating advanced breast cancer. The company said the drug met its target of extended progression-free survival.
Sean Bohen, executive vice president for global medicines development and chief medical officer at AstraZeneca, said the results from the trial bring AstraZeneca closer to offering more and earlier treatment options for post-menopausal women suffering with breast cancer.
Elsewhere, sodium zirconium cyclosilicate is an investigational medicine being developed by ZS Pharma, a subsidiary of AstraZeneca, for the treatment of hyperkalaemia, or high potassium levels in the blood.
The letter from the US FDA refers to observations made during a pre-approval manufacturing inspection, AstraZeneca said, and acknowledges recently submitted data which has yet to be reviewed by the US regulator.
By Sam Unsted; samunsted@alliancenews.com; @SamUAtAlliance
Copyright 2016 Alliance News Limited. All Rights Reserved.
Astrazeneca (AZN)